Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Claudin18.2
Claudin18.2
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
Fierce Biotech
AstraZeneca
Claudin18.2
KYM Biosciences
antibody-drug conjugate
pancreatic cancer
Flag link:
